about
Study of Protein Biomarkers of Diabetes Mellitus Type 2 and Therapy with Vitamin B1Circulating microRNAs as biomarkers, therapeutic targets, and signaling moleculesBrain imaging of pain: state of the art.Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism InvestigationsNew Developments in Biomarkers for Atopic DermatitisEvaluation of optical detection platforms for multiplexed detection of proteins and the need for point-of-care biosensors for clinical useCombined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy aloneRemoving obstacles in neuroscience drug discovery: the future path for animal models.Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.Risk in CNS drug discovery: focus on treatment of Alzheimer's disease.A peptide probe for the detection of neurokinin-1 receptor by disaggregation enhanced fluorescence and magnetic resonance signals.The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentEffect of cocaine dependence on brain connections: clinical implications.A role for fMRI in optimizing CNS drug development.Identifying network-based biomarkers of complex diseases from high-throughput data.Recent advances in pharmacokinetic extrapolation from preclinical data to humans.Role of functional magnetic resonance imaging in drug discovery.The 1H NMR profile of healthy dog cerebrospinal fluid.The opportunities and challenges of developing imaging biomarkers to study lung function and disease.Swarm intelligence based wavelet coefficient feature selection for mass spectral classification: an application to proteomics dataKnowledge-based variable selection for learning rules from proteomic data.A knowledge-driven approach to extract disease-related biomarkers from the literatureLipidomics reveals a link between CYP1B1 and SCD1 in promoting obesity.Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling.Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines.Can peripheral leukocytes be used as Alzheimer's disease biomarkers?Biomarkers to Target Heterogeneous Breast Cancer Stem CellsBiomarkers of HIV-associated Cancer.Universal Biotin-PEG-Linked Gold Nanoparticle Probes for the Simultaneous Detection of Nucleic Acids and Proteins.Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradationIdentification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker.EEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Biomarkers in development of psychotropic drugs.Molecular biomarkers for grass pollen immunotherapy.Advancing cancer drug discovery towards more agile development of targeted combination therapies.Ongoing search for diagnostic biomarkers in idiopathic normal pressure hydrocephalus.Genome-wide gene expression analysis suggests an important role of suppressed immunity in pathogenesis of Kashin-Beck disease.Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
P2860
Q26798146-281AECEB-F5FF-4303-8CE5-3C59C5C6DDFBQ26997097-6207FF00-4E48-4034-8684-17AE81CFA664Q28067180-217F0974-DA2E-4C22-AA6C-B1DC3CE2DA63Q28068009-3887151D-DEFE-43A8-AA36-989347A99171Q28396611-BB684E6E-BA49-4AD4-85C2-81A0E7E32839Q28652076-F944203C-9C64-4A61-9C4D-D6F32A80B28EQ28710288-92FC1716-B067-48DD-8E74-FB314CBE03D2Q28755229-5CCD6941-4A6A-4FA0-B020-0374B9ADB290Q30366697-28A26775-42BA-4F8C-A88F-B4A9AFCD9AAEQ30645097-9485B464-7E9A-4910-B505-7DADE7C22469Q30855147-183E9075-22AB-448D-932F-9EB3ABBC84ECQ30856625-6E410817-1159-4AC1-9AD1-3047F68D779FQ30977143-08CA03C9-9C9A-4FDB-9B22-51D7BC500118Q31012723-B00AEB9D-FAA4-402C-9EA1-1DB56A9C1423Q31036354-4BE0DCD2-A181-44DD-9F72-8EE7AFDD73D5Q31038202-75374EB2-BB67-4764-8FAA-AECEAD98F9A5Q31049599-5530E5AE-81B0-42D6-83FE-A88127015041Q31109439-E0CCE161-72A5-42D2-AED9-EDC96022C6BBQ31146776-EF3164F6-ED0B-4DEE-A256-00930E5D0429Q33283655-BF31ED7F-7831-45FB-845B-BDA88748952EQ33500492-FAECEE9B-044B-427F-9886-5DE56A3F165EQ33504371-AA63682A-6B1F-4BC1-919C-0BDA5F4D9586Q33563062-3265A4C4-FA52-4292-AD8E-AD729D115D3DQ33598703-EF177EE5-1D8A-4A7E-B620-8AD61371D8C9Q33602325-A45664EC-4CA4-4207-AAC5-5F34896326B8Q33659363-185DA8FE-5DD2-4C9F-94C0-3E9A8A6A624EQ33689076-5898074E-7981-4C6D-BC66-F257D2120558Q33811149-C9E76F7C-254F-40B3-94DD-5BC59A578926Q33856851-49BFF602-4E47-418E-9039-5E22E7A89AAAQ33859313-6E8DA6D1-615D-45B3-9299-4806B08AC4FEQ33882805-34471C59-6A1B-4059-82D8-707972441B02Q33906854-0E9C18B9-C350-4CD0-9E0B-756A0195FDFEQ33915806-CECBDC04-580E-45E3-81B1-75E26F4A31BAQ33963735-1D1DBF9E-C3A9-443C-A8C4-3093B0AC25C2Q33993209-D6440154-398D-424C-9C40-D9A7C83175D1Q34093047-8F6B6DF6-1A31-49E9-95F6-21932C4551CEQ34100574-2311F417-1F43-4FE1-A700-1B1D1ADDCA42Q34115835-7246CDE0-F94F-4009-992A-7FE0E53770C9Q34123460-F6A27B8C-0299-4FDF-9E5B-55FE8A42B930Q34134483-E49740BF-FE40-495C-9390-A0C3E0E9F179
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical biomarkers in drug discovery and development.
@ast
Clinical biomarkers in drug discovery and development.
@en
type
label
Clinical biomarkers in drug discovery and development.
@ast
Clinical biomarkers in drug discovery and development.
@en
prefLabel
Clinical biomarkers in drug discovery and development.
@ast
Clinical biomarkers in drug discovery and development.
@en
P356
P1476
Clinical biomarkers in drug discovery and development.
@en
P2093
Richard Frank
Richard Hargreaves
P2888
P304
P356
10.1038/NRD1130
P577
2003-07-01T00:00:00Z